Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Goal Dates

Executive Summary

Estimated FDA review deadlines for pending applications. Updated weekly.

Advertisement

Related Content

Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee
Historical Control In Psoriatic Arthritis May Hinge On Background Therapy
Could FDA Force Pfizer To Push Shingles Vaccination With Xeljanz Psoriatic Arthritis Approval?
Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain
Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?
Abuse-Deterrent Opioids: Rexista To Test New FDA Leadership's Approach

Topics

Advertisement
UsernamePublicRestriction

Register

PS119987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel